FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $44.45, for a total value of $533,400.00. Following the completion of the sale, the director now directly owns 36,000 shares of the company’s stock, valued at $1,600,200. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kalevi Kurkijarvi also recently made the following trade(s):

  • On Friday, November 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $46.65, for a total value of $93,300.00.
  • On Tuesday, October 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $52.24, for a total value of $104,480.00.
  • On Monday, September 18th, Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock. The shares were sold at an average price of $46.65, for a total value of $186,600.00.

FibroGen Inc (FGEN) traded up $0.45 during mid-day trading on Friday, reaching $42.40. The company’s stock had a trading volume of 2,858,243 shares, compared to its average volume of 628,497. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen Inc has a fifty-two week low of $19.25 and a fifty-two week high of $60.15.

FGEN has been the subject of a number of research analyst reports. Jefferies Group reaffirmed a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. Mizuho reaffirmed a “hold” rating and issued a $61.00 target price on shares of FibroGen in a research report on Thursday, November 9th. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 price target on shares of FibroGen in a research note on Thursday, September 14th. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $65.67.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Iguana Healthcare Management LLC purchased a new position in shares of FibroGen in the 3rd quarter worth approximately $2,152,000. California Public Employees Retirement System raised its holdings in shares of FibroGen by 1.8% in the 3rd quarter. California Public Employees Retirement System now owns 94,900 shares of the biopharmaceutical company’s stock worth $5,106,000 after purchasing an additional 1,700 shares during the period. Perceptive Advisors LLC bought a new stake in shares of FibroGen in the 3rd quarter worth approximately $462,000. Jane Street Group LLC raised its holdings in shares of FibroGen by 102.4% in the 3rd quarter. Jane Street Group LLC now owns 17,613 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 8,910 shares during the period. Finally, BBR Partners LLC bought a new stake in shares of FibroGen in the 3rd quarter worth approximately $299,000. Hedge funds and other institutional investors own 57.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/fibrogen-inc-fgen-director-kalevi-kurkijarvi-sells-12000-shares-of-stock/1766651.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.